Early trials indicate that this peptide – a dual stimulator of GLP-1 and glucose-dependent insulinotropic polypeptide receptors – offers a considerable improvement in metabolic loss programs . Beyond existing medications , this dual-action compound seems to influence food intake and energy expenditure by means of separate mechanisms . While ad